anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present disclosure relates to systems and methods for radiotherapy planning. The systems may obtain a delineation of a region of interest (ROI) in an image of an object. The ROI may include at least one target region. The systems may obtain modified delineation of the ROI based on one or more modifications to the delineation of the ROI. The systems may determine a target radiotherapy plan of the object by performing a radiotherapy dose optimization on the ROI. The modifications of the delineation of the ROI and the radiotherapy dose optimization of the ROI may be performed at least partially overlap temporally.
PURPOSE OF REVIEW: To provide a comprehensive overview of the underlying genetic defects of pulmonary (vascular) diseases and novel treatment avenues.
RECENT FINDINGS: Pulmonary arterial hypertension (PAH) is the prime example of a pulmonary vascular disease, which can be caused by genetic mutations in some patients. Germline mutations in the BMPR2 gene and further genes lead to vessel remodelling, increase of pulmonary vascular resistance and onset of heritable PAH. The PAH genes with the highest evidence and strategies for genetic testing and counselling have been assessed and evaluated in 2023 by international expert consortia. Moreover, first treatment options have just arisen targeting the molecular basis of PAH.
SUMMARY: Apart from PAH, this review touches on the underlying genetic causes of further lung diseases including alpha 1 antitrypsin deficiency, cystic fibrosis, familial pulmonary fibrosis and lymphangioleiomyomatosis. We point out the main disease genes, the underlying pathomechanisms and novel therapies trying not only to relieve symptoms but to treat the molecular causes of the diseases.
PURPOSE:To obtain the subject novel compound comprising a 19-membered ring macrolactone and having an antifungal activity and an antitumor activity by culturing a microorganism belonging to the genus Amycolatopsis in a medium, and subsequently extracting the cultured product from the culture solution. CONSTITUTION:A microorganism [e.g. Amycolatopsis sp. TA-0234 (FERM P-13322)] belonging to the genus Amycolatopsis is inoculated into a sterile liquid medium, and subsequently cultured at 28 deg.C for 96hr under shaking. The culture solution is added to a medium in a mini jar, cultured at 28 deg.C for 96hr under stirring and aeration bubbles, and subsequently extracted with acetone. The acetone is distilled off from the extract solution, and the residue is extracted with ethyl acetate. The extract solution is concentrated into a brown syrup-like substance. The substance is dissolved in methanol and subjected to a gel filtration. An separated active fraction is passed through a reverse phase silica gel column, and an adsorbed substance is eluted and subsequently purified with a high performance liquid column chromatography to provide the objective novel 19-membered ring macrolactone having an antifungal activity and an antitumor activity.
AIM: To verify the association between ideal sleep time and physical literacy components while also considering multiple mediators, such as quality of life and obesity, using a sample of adolescents.
METHODS: This cross-sectional study consisted of 470 adolescents aged 11-17 years from southern Brazil. Sleep time, health-related quality of life, and physical literacy components (i.e., physical education enjoyment, sports participation, sedentary behavior, moderate to vigorous physical activity, sex, and age) were evaluated through self-reported questionnaires. In addition, body mass index (BMI), and waist circumference were determined. The theoretical/statistical support of the structural equation model was evaluated according to fit parameters and strength of association.
RESULTS: A direct association was observed between more sleep time and lower levels of obesity. The obesity indicators also had a negative association with HqOL, and HqOL had a positive association with physical literacy. The indirect associations indicated that the ideal sleep time was positively associated with HqOL and physical literacy components, considering the negative mediation effect of obesity. The model explains physical literacy in 31% of the variance (R = 0.31).
CONCLUSION: There was an indirect association between ideal sleep duration and quality of life and between both variables with physical literacy. These relationships occur even considering the negative influence of obesity. Therefore, a child who sleeps adequately has a higher likelihood of being physically active, regardless of obesity, potentially enhancing overall quality of life across various domains.
All patients were preoxygenated for three minutes. Midazolam 0.03 mg/kg, fentanyl 1.5 mcg/kg , propofol 2 mg/kg and rocuronium 0.6 mg/kg were administered iv for induction of anesthesia. After intubation all patients were mechanically ventilated with 50% O2+50% air + 6-7% desflurane in a 4 L/min fresh gas flow until the MAC value reached 1. When the MAC value of desflurane was 1, fresh gas flow was decreased to 0.5 L/min (60% O2+40% air) in Group D. Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
A total of eight volunteers were included according to the inclusion and exclusion criteria. The subjects were vibrated while standing upright with the WBV device (PowerPlate® Pro5). The 30, 35 and 40 Hz WBVs were applied for thirty seconds for each frequency with an amplitude of 2 mm. In the same session, 100, 135 and 150 Hz local vibrations were applied to the right Achilles tendon for thirty seconds for each frequency. 100, 135 and 150 Hz local vibrations were then applied to the right heel for thirty seconds for each frequency with an interval of five seconds. Vibration stimuli were recorded accelerometers. Reflex muscle responses were recorded from the right soleus muscle at a sampling rate of 40 KHz. Recording electrodes were placed on the belly of the right soleus muscle and the ground electrode was placed on the right medial malleolus.

The data were recorded with the PowerLab device, the records were processed and analyzed offline from the LabChart program. After the EMG records are filtered and rectified, reflex latencies were measured by cumulative averaging method using the accelerometer records as triggers (Karacan I, Cakar HI, Sebik O, Yilmaz G, Cidem M, Kara S, Türker KS.A new method to determine reflex latency induced by high rate stimulation of the nervous system.Front Hum Neurosci.2014 Jul 18; 8: 536.doi: 10.3389 / fnhum.2014.00536). After determining the Achilles tendon vibration reflex latency and the reflex latency induced by WBV, it was compared with statistical methods.
PROBLEM TO BE SOLVED: To obtain a preparation for external use for lips effective in reducing crazing and roughening symptoms of the tips due to viral causes or ultraviolet rays. SOLUTION: This preparation for external use for lips comprises 0.01-5wt.% of a chondroitin polysulfate and 0.01-10wt.% each of at least one of an antiinflammatory agent and zinc oxide. One or more of glycyrrhizic acid or its derivative, glycyrrhetinic acid or its derivative, allantoin, bisabolol, ε- aminocaproic acid and tranexamic acid are selected as the antiinflammatory agent. A crude drug having antiinflammatory actions, an ultraviolet light absorber or an ultraviolet light cutting agent (e.g. particulate titanium oxide), a humectant (e.g. an amino acid), etc., are further preferably blended therein. The preparation can be formulated into a solution for external use such as a lotion, a liniment or a milky lotion or a semisolid preparation for external use such as a cream, an ointment, a jelly or a stick for use.
BACKGROUND & AIMS: In the American Gastroenterological Association/American Association for the Study of Liver Diseases (AGA/AASLD) Clinical Care Pathway, Fibrosis-4 index (FIB-4) is used to stratify patients at risk for metabolic dysfunction-associated steatotic liver disease (MASLD) as low-, indeterminate-, or high-risk for developing advanced liver fibrosis. We assessed the performance of FIB-4 in a general population.
METHODS: Using the 2017 to 2020 National Health and Nutrition Examination Surveys dataset, we selected subjects ≥18 years who had FibroScan data. We followed AGA/AASLD guidelines to identify subjects with characteristics that place them at risk for MASLD-associated liver fibrosis. Other causes of liver disease were excluded. Our final cohort had 3741 subjects. We then categorized these subjects based on recommended FIB-4 cutoffs. FibroScan liver stiffness measurement (LSM) served as the outcome measurement.
RESULTS: Among the 2776 subjects (74.2%) classified as low risk by FIB-4, 277 subjects (10%) were not classified at low risk by LSM, and 75 subjects (2.7%) were classified as high risk by LSM. Among the 86 subjects classified as high risk by FIB-4, 68 subjects (79.1%) were not at high risk by LSM, and 54 subjects (62.8%) were at low risk by LSM. Subjects misclassified by FIB-4 as low risk were older; had a higher body mass index, waist circumference, glycohemoglobin A1c level, alanine transaminase, aspartate transaminase, diastolic blood pressure, controlled attenuation parameter score, white blood cell count, alkaline phosphatase, and fasting glucose level; but had lower high-density lipoprotein, and albumin level (all P < .05). Misclassified subjects were also more likely to have prediabetes/diabetes.
CONCLUSION: Using FIB-4 in the AGA/AASLD guidelines to risk-stratify subjects at risk for MASLD-associated fibrosis results in many subjects being misclassified into the low- and high-risk categories. Therefore, it may be worthwhile considering caution in interpretation and/or alternative strategies.
Compositions for oral delivery of silica nanoparticles and/or aluminosilicate nanoparticles, and methods of use thereof. The individual nanoparticles comprise a silica core or an aluminosilicate core and, optionally, polyethylene glycol (PEG) groups each disposed on a surface of the nanoparticle. In various examples, the nanoparticles have a size of about 20 nm or less. In various examples, the nanoparticles can be delivered to an individual's gastrointestinal tract, pass through the mucus layer thereof, and permeate the epithelial lining thereof. In various examples, the nanoparticles comprise various targeting, diagnostic, or therapeutic group(s) and can retain one or more said activit(ies) after delivery. Methods of oral delivery and methods of treating a disease can comprise orally administering composition(s) to an individual. Non-limiting examples of diseases include infections, cancers, neurological conditions/discases, neurodegenerative discases, psychological conditions/diseases, inflammatory conditions/diseases, cardio-vascular diseases, and the like.
This study aimed to examine the efficacy of video games in improving cognitive function in chronic patients with schizophrenia and to evaluate the biomarker of video games for cognitive function. The patients in the game group were requested to play single-player video games on their smartphones for 1 h per day, five times a week for 6 weeks. Those in the control group watched television for 1 h per day, five times a week for 6 weeks. Cognitive function was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and Stroop Color and Word Test (SCWT). Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF), General Self-Efficacy Scale (GSE), Problematic Mobile Gaming Questionnaire (PMGQ), and Patient Health Questionnaire-9 (PHQ-9). The game group demonstrated improved RBANS total score during the trial. There were no significant group effects among all SCWT scores. The game group demonstrated greater improvement on the PANSS Negative Scale, and global function (GAF score). The PMGQ scores were lower than the cutoff score at all time points in both groups. There were no significant group differences in the PHQ-9 and GSE scores. The serum BDNF levels were significantly higher in the game group following 6 weeks of video game intervention. The BDNF serum levels of all participants were positively associated with the RBANS total scores. This preliminary study suggested that video games can improve cognitive function in schizophrenia patients. Serum BDNF levels may be a suitable biomarker for predicting an improvement in cognitive function in schizophrenia patients.Trial registration: This study was registered on March 11, 2021 (ChiCTR2100044113).Clinical trials: Smartphone video games improve cognitive function in patients with chronic schizophrenia; https://www.chictr.org.cn/hvshowproject.aspx?id=95623 ; ChiCTR2100044113.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, and aims at treating chronic hepatitis type C in HIV positive patients. A complex of pathogenetic therapy is prescribed. It is added with the preparation Wobenzyme. A dose is 5-7 pills 3 times a day. A course is 2 to 6 months. ^ EFFECT: method allows to reduce intoxication and jaundice due to improved clinical-biochemical values. ^ 3 tbl, 2 ex
The invention relates to an integrated novel form preparation technology for bulbus fritillaria and snakegourd fruit powder and a production method thereof. The effective components of the beimu gualou powder comprise the following raw materials in parts by weight: 4.5 parts of bulbus fritillaria, 3 parts of snakegourd fruit, 2.5 parts of pollen, 2.5 parts of tuckahoe, 2.5 parts of dried tangerine peel and 2.5 parts of platycodon root. The production process of the beimu gualou powder comprises the steps of supersonic airflow pulverizing, alcohol water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spraying and drying, nanometer grinding, uniform high-pressure emulsification, nano particle preparation and the like. According to the invention, the multi-synergism, multi-target and other advantages embodied by a nano-carrier coupling technique are attached to apply. After the bulbus fritillaria and snakegourd fruit powder is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The bulbus fritillaria and snakegourd fruit powder can be taken by internally and externally feeding and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of human body. In addition, the bulbus fritillaria and snakegourd fruit powder can be prepared into films and transdermal agents which are respectively attached to different parts of human body according to the midnight-noon ebb-flow and qi and blood flowing rule of human body and can be directly absorbed through skin.
A 100 cc multimodal analgesic cocktail will be injected into the superficial and deep peri-incisional tissues after the completion of femur fracture fixation/instrumentation while the patient remains under general anesthesia and prior to wound closure. This cocktail includes 400 mg of 0.75% ropivacaine (53.33 mL), 0.6 mg of 1 mg/mL epinephrine (0.6 mL), 5 mg of 0.5 mg/mL morphine sulfate (10 mL), and 36.07 mL 0.9% sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.
OBJECTIVE: Hemifacial spasm (HFS) results from vascular compression at the root exit of the facial nerve. Although the underlying etiology has yet to be identified, it has been suggested that congenital vascular anomalies are involved. We have hypothesized common trunk anomaly of the anterior inferior cerebellar artery (AICA) and posterior inferior cerebellar artery (PICA) which may play a role in HFS. However, no previous studies have directly compared the incidence of this anomaly between HFS patients and normal subjects. The present study was designed to address this gap in the literature.
METHODS: This case-control study compared magnetic resonance angiography data from 65 HFS patients and 65 normal subjects. Dominant AICA/PICA is defined as the absence of PICA/AICA, with the remaining AICA/PICA supplying both vascular territories. The term "common trunk" encompasses both dominant AICA and dominant PICA. The frequency of common trunk and dominant AICA/PICA was compared between the 2 groups.
RESULTS: There were no significant differences in the incidence of a common trunk (68.5% and 64.6%), dominant AICA (30.8% and 32.3%) and dominant PICA (37.7% and 32.3%) between the 2 groups. Additionally, no differences were found in the frequency of atherosclerosis risk factors.
CONCLUSIONS: There was no apparent association between common trunk anomaly and HFS. It is suspected that some vascular anomalies other than a common trunk are involved in HFS.
A modified peptide AT-01 has been synthesized from the microbiomic secretory protein MPT63 of Mycobacterium tuberculosis. This peptide (about 30 amino acids) contains a portion of the immunogenic region of MPT63 (131 amino acids). It has been found to stabilize SMAR1 (Scaffold Matrix Attachment Region Binding Protein 1), a tumor suppressor protein which is well characterized as anti-cancer. AT-01 was modified further to generate 6 new, independent peptides. Among the peptides AT-01 C and AT-01 D were found to be more effective than the other peptides. AT-01 D also attenuated cell migration of MDA-MB231 cells which supports the anti-metastatic activity. Inhibition of the cell growth from the Colony Formation Assays too supported its anticancer activity. It does not cause toxicity to the cells at high doses which demonstrates great potential value as a safe and effective cancer therapy.
PURPOSE: To obtain an inhibitor containing a specific active ingredilent, high in safety, having high glycerophosphoric acid dehydrogenase inhibitory activity, capable of its ready formulation in foods, and useful for preventing or treating obesity. CONSTITUTION: This inhibitor contains as active ingredient a compound selected from cholesterol-3-sulfate, dihydrocholesterol-3-sulfate and their salts. The (dihydro)cholesterol-3-sulfate is obtained, for example, by sulfating (dihydro) cholesterol. The dose of this inhibitor is pref. 0.5-5000mg/day for adult and 0.5-3000mg/day for child in terms of the active ingredient. It is preferable that the proportional amount of the active ingredient in this inhibitor be 0.3-15wt.% for oral administration and 0.01-1.0wt.% for parenteral, administration. Pharmaceutic at manufacturing through coating the active ingredient clan yield the objective inhibitor with high stability, therefore being favorable.
A total of 29 patients, 7 women, and 22 men were included according to the inclusion and exclusion criteria. The patients were randomly assigned to the control group (n = 14) and the Mirror group (n = 15). Five sessions of neuromuscular electrical stimulation, unaffected side ankle dorsiflexors were applied to the patients in both groups. In addition to the NMES, mirror therapy was applied to the experimental group simultaneously with NMES. Before and after treatment, both ankle dorsiflexor strength was measured with a force sensor. For force measurements, a force transducer (FC2211-0000-0100-L Compression Load Cell, TE Connectivity company, France) was used. Force transducer signals were received with a data acquisition device (POWERLAB® data acquisition system ADInstruments, Oxford, UK) and evaluated offline on the computer. The measurement values were expressed in kilogram.force (kg.f) and this value was normalized according to body weight.
PURPOSE:To provide the titled hydrolyzed protein containing a specific peptide obtained by hydrolyzing a protein with an enzyme. CONSTITUTION:The objective hydrolyzed protein effective to depress the cholesterol level in blood and containing >=30W/W% oligopeptide (having a molecular weight of 200-1,500, preferably 700-1,400, and an Arg/Lys ratio of >=0.6, preferably >=0.8) is obtained by hydrolyzing a protein (e.g. soybean protein, etc.) with an enzyme (e.g. pepsin). The product is soluble completely in a neutral or acidic aqueous medium of about 2pH, and also soluble in 10% trichloroacetic acid solution. It can be used as a food such as oral nutrient food, transvascular nutrient agent, etc. to lower the cholesterol level in blood by properly selecting the form of the product.
The invention relates to a medicine for treating early hypertension. The medicine is prepared from the following raw medicinal materials in parts by weight: 9 parts of gastrodia tuber, 15 parts of buffalo horn, 15 parts of selfheal and 6 parts of thunberg fritillary bulb. In the formula, the gastrodia tuber acts on the liver channel, has the effects of smoothing the liver, calming endogenous wind and relieving convulsion, and is used for treating headache, dizziness and limb numbness; the buffalo horn is bitter in taste and cold in nature, acts on the heart channel and the liver channel, and has the effects of clearing heat, detoxifying, cooling blood and arresting convulsion; the selfheal acts on the liver channel and the gallbladder channel, has the effects of clearing the heat, improving eyesight, removing stasis and diminishing swelling; the thunberg fritillary bulb has the effects of clearing the heat, removing the stasis, eliminating phlegm and stopping coughing. Modern pharmacology shows that gastrodia tuber injection can reduce the blood pressure, decrease the heart rate, increase the cardiac output, reduce the myocardial oxygen consumption and improve the anti-anoxia capacity of mice. The raw medicinal materials are used together to achieve the effects of smoothing the liver, calming the endogenous wind, restraining the hyperactivity of yang, and eliminating the phlegm. Clinical trials prompt that the medicine can be safely and effectively applied to treatment of the early hypertension.
PROBLEM TO BE SOLVED: To prepare a hair growing and restoring agent containing a specific compound, directly acting on the differentiation and multiplication of the mother cell of hair and having an excellent growing and restoring effect and an excellent effect on the prevention of loss of hair. SOLUTION: This hair growing and restoring agent is preparaed by including a compound of formula I (wherein, R<1> , R<3> and R<4> are each H, OH or a lower alkoxy; R<2> is H or a lower alkyl), (pref. a compound of formula II or formula III). It is pref. that the compound of formula I is included in a content of, 0.01-3 wt.%, and the hair growing and restoring agent is formulated with at least one of a circulation accelerator, an antibacterial agent, a keratolytic, an antiseborrheic, etc., and is dissolved in water or a mixed solvent of water-lower alcohol, etc., in the usage of the agent. The agent has a form of preparations selected from a group consisting of solution as a principal form, lotion, cream and jelly. The solution is included together with carbonic acid gas and the fluid property of the agent is pref. pH 4.5-6.5.